. 2017 Dec 14;49(4):255–261. doi: 10.3947/ic.2017.49.4.255

Table 1. Comparison between Cytomegalovirus (CMV) pp65-positive group and CMV pp65-negative group.

Characteristics		CMV pp65-Negative (n = 32; 36.8%)	CMV pp65-Positive (n = 55; 63.2%)	P-value	CMV Total (n = 87; 100%)
Age (yr)
	Mean (SD)	24.9 (17.3)	36.7 (16.1)	0.001^a	32.6 (17.6)
	Range	2–67	2–68		2–68
	Median	17	39		34
Sex
	Male	17 (53%)	34 (63%)	0.427	51 (59%)
	Female	15 (47%)	21 (38%)	0.427	36 (41%)
Donor Type
	Living	9 (28%)	4 (7%)	0.009^b	13 (15%)
	Deceased	23 (72%)	51 (93%)	0.009^b	74 (85%)
CMV Status prior to transplant
	D+/R+	21 (66%)	42 (76%)	0.554	63 (72%)
	D+/R−	5 (16%)	8 (15%)		13 (15%)
	D−/R+	2 (6%)	1 (2%)		3 (4%)
	D−/R−	4 (12%)	4 (7%)		8 (9%)
Immunosuppressive Therapy
	FK/MMF/Pred	27 (84%)	45 (82%)	0.761	72 (83%)
	FK/Aza/Pred	5 (16%)	10 (18%)	0.761	15 (17%)
ATG use^c
	Yes	4 (12%)	7 (13%)	0.975	11 (13%)
	No	28 (88%)	48 (87%)	0.975	76 (87%)

D, donor; R, recipient. FK, tacrolimus; MMF, mycophenolate mofetil; Pred, prednisone; Aza, azathioprine; ATG, anti-thymocyte globulin.

P values by Chi-square test.

^aMann–Whitney test.

^bThere was no difference in age of the patients (P >0.05) and OR = 4.9.

^cATG used for induction therapy or for treatment of acute rejection.